Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy

Gerald L Denardo, Christine L. Hartmann Siantar, Sally J. DeNardo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Radionuclide therapy extends the usefulness of radiation from localized disease to multifocal disease by combining radionuclides with disease-seeking drugs such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy the effectiveness of targeted radionuclides is ultimately limited by the amount of undesired radiation given to a critical dose-limiting normal tissue most often the bone marrow. Because radionuclide therapy relies on biological delivery of radiation its optimization and characterization are necessarily different than for conventional radiation therapy. However the principals of radiobiology and of absorbed radiation dose remain important for predicting radiation effects. Fortunately most radionuclides emit gamma rays that allow the measurement of isotope concentrations in both tumor and normal tissues in the body. By administering a small "test dose" of the intended therapeutic drug the clinician can predict the radiation dose distribution in the patient. This can serve as a basis to predict therapy effectiveness optimize drug selection and select the appropriate drug dose in order to provide the safest most effective treatment for each patient. Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity practical considerations may dictate simpler solutions under some circumstances. There is agreement that radiation dosimetry (radiation absorbed dose distribution cGy) should be utilized to establish the safety of a specific radionuclide drug during drug development but it is less generally accepted that absorbed radiation dose should be used to determine the dose of radionuclide (radioactivity GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). However radiation dosimetry can always be utilized as a tool for developing drugs assessing clinical results and establishing the safety of a specific radionuclide drug. Bone marrow dosimetry continues to be a "work in progress." Blood-derived and/or body-derived marrow dosimetry may be acceptable under specific conditions but clearly do not account for marrow and skeletal targeting of radionuclide. Marrow dosimetry can be expected to improve significantly but no method for marrow dosimetry seems likely to account for decreased bone marrow reserve.

Original languageEnglish (US)
Pages (from-to)107-118
Number of pages12
JournalCancer Biotherapy and Radiopharmaceuticals
Volume17
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Radiometry
Radioisotopes
Radiation
Bone Marrow
Pharmaceutical Preparations
Therapeutics
Radiotherapy
Radiobiology
Safety
Gamma Rays
Radiation Effects
Isotopes
Radioactivity

Keywords

  • Cancer
  • Dosimetry
  • Radionuclide
  • Radiotherapy
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. / Denardo, Gerald L; Hartmann Siantar, Christine L.; DeNardo, Sally J.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 17, No. 1, 2002, p. 107-118.

Research output: Contribution to journalArticle

Denardo, Gerald L ; Hartmann Siantar, Christine L. ; DeNardo, Sally J. / Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. In: Cancer Biotherapy and Radiopharmaceuticals. 2002 ; Vol. 17, No. 1. pp. 107-118.
@article{196c91ca4ed6475688f57cdd58d5ab5b,
title = "Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy",
abstract = "Radionuclide therapy extends the usefulness of radiation from localized disease to multifocal disease by combining radionuclides with disease-seeking drugs such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy the effectiveness of targeted radionuclides is ultimately limited by the amount of undesired radiation given to a critical dose-limiting normal tissue most often the bone marrow. Because radionuclide therapy relies on biological delivery of radiation its optimization and characterization are necessarily different than for conventional radiation therapy. However the principals of radiobiology and of absorbed radiation dose remain important for predicting radiation effects. Fortunately most radionuclides emit gamma rays that allow the measurement of isotope concentrations in both tumor and normal tissues in the body. By administering a small {"}test dose{"} of the intended therapeutic drug the clinician can predict the radiation dose distribution in the patient. This can serve as a basis to predict therapy effectiveness optimize drug selection and select the appropriate drug dose in order to provide the safest most effective treatment for each patient. Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity practical considerations may dictate simpler solutions under some circumstances. There is agreement that radiation dosimetry (radiation absorbed dose distribution cGy) should be utilized to establish the safety of a specific radionuclide drug during drug development but it is less generally accepted that absorbed radiation dose should be used to determine the dose of radionuclide (radioactivity GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). However radiation dosimetry can always be utilized as a tool for developing drugs assessing clinical results and establishing the safety of a specific radionuclide drug. Bone marrow dosimetry continues to be a {"}work in progress.{"} Blood-derived and/or body-derived marrow dosimetry may be acceptable under specific conditions but clearly do not account for marrow and skeletal targeting of radionuclide. Marrow dosimetry can be expected to improve significantly but no method for marrow dosimetry seems likely to account for decreased bone marrow reserve.",
keywords = "Cancer, Dosimetry, Radionuclide, Radiotherapy, Therapy",
author = "Denardo, {Gerald L} and {Hartmann Siantar}, {Christine L.} and DeNardo, {Sally J.}",
year = "2002",
doi = "10.1089/10849780252824127",
language = "English (US)",
volume = "17",
pages = "107--118",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy

AU - Denardo, Gerald L

AU - Hartmann Siantar, Christine L.

AU - DeNardo, Sally J.

PY - 2002

Y1 - 2002

N2 - Radionuclide therapy extends the usefulness of radiation from localized disease to multifocal disease by combining radionuclides with disease-seeking drugs such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy the effectiveness of targeted radionuclides is ultimately limited by the amount of undesired radiation given to a critical dose-limiting normal tissue most often the bone marrow. Because radionuclide therapy relies on biological delivery of radiation its optimization and characterization are necessarily different than for conventional radiation therapy. However the principals of radiobiology and of absorbed radiation dose remain important for predicting radiation effects. Fortunately most radionuclides emit gamma rays that allow the measurement of isotope concentrations in both tumor and normal tissues in the body. By administering a small "test dose" of the intended therapeutic drug the clinician can predict the radiation dose distribution in the patient. This can serve as a basis to predict therapy effectiveness optimize drug selection and select the appropriate drug dose in order to provide the safest most effective treatment for each patient. Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity practical considerations may dictate simpler solutions under some circumstances. There is agreement that radiation dosimetry (radiation absorbed dose distribution cGy) should be utilized to establish the safety of a specific radionuclide drug during drug development but it is less generally accepted that absorbed radiation dose should be used to determine the dose of radionuclide (radioactivity GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). However radiation dosimetry can always be utilized as a tool for developing drugs assessing clinical results and establishing the safety of a specific radionuclide drug. Bone marrow dosimetry continues to be a "work in progress." Blood-derived and/or body-derived marrow dosimetry may be acceptable under specific conditions but clearly do not account for marrow and skeletal targeting of radionuclide. Marrow dosimetry can be expected to improve significantly but no method for marrow dosimetry seems likely to account for decreased bone marrow reserve.

AB - Radionuclide therapy extends the usefulness of radiation from localized disease to multifocal disease by combining radionuclides with disease-seeking drugs such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy the effectiveness of targeted radionuclides is ultimately limited by the amount of undesired radiation given to a critical dose-limiting normal tissue most often the bone marrow. Because radionuclide therapy relies on biological delivery of radiation its optimization and characterization are necessarily different than for conventional radiation therapy. However the principals of radiobiology and of absorbed radiation dose remain important for predicting radiation effects. Fortunately most radionuclides emit gamma rays that allow the measurement of isotope concentrations in both tumor and normal tissues in the body. By administering a small "test dose" of the intended therapeutic drug the clinician can predict the radiation dose distribution in the patient. This can serve as a basis to predict therapy effectiveness optimize drug selection and select the appropriate drug dose in order to provide the safest most effective treatment for each patient. Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity practical considerations may dictate simpler solutions under some circumstances. There is agreement that radiation dosimetry (radiation absorbed dose distribution cGy) should be utilized to establish the safety of a specific radionuclide drug during drug development but it is less generally accepted that absorbed radiation dose should be used to determine the dose of radionuclide (radioactivity GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). However radiation dosimetry can always be utilized as a tool for developing drugs assessing clinical results and establishing the safety of a specific radionuclide drug. Bone marrow dosimetry continues to be a "work in progress." Blood-derived and/or body-derived marrow dosimetry may be acceptable under specific conditions but clearly do not account for marrow and skeletal targeting of radionuclide. Marrow dosimetry can be expected to improve significantly but no method for marrow dosimetry seems likely to account for decreased bone marrow reserve.

KW - Cancer

KW - Dosimetry

KW - Radionuclide

KW - Radiotherapy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036189960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189960&partnerID=8YFLogxK

U2 - 10.1089/10849780252824127

DO - 10.1089/10849780252824127

M3 - Article

C2 - 11915167

AN - SCOPUS:0036189960

VL - 17

SP - 107

EP - 118

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -